Fabry's disease historical perspective: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(2 intermediate revisions by one other user not shown)
Line 2: Line 2:
{{Fabry's disease}}
{{Fabry's disease}}


{{CMG}} {{AE}}  
{{CMG}} {{AE}} {{GhazalS}}


==Overview==
==Overview==
Line 23: Line 23:


==References==
==References==
<references />
{{Reflist|2}}
 
[[Category:Needs english review]]

Latest revision as of 10:23, 14 July 2022

Fabry's disease Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Fabry's disease from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Fabry's disease historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Fabry's disease historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Fabry's disease historical perspective

CDC on Fabry's disease historical perspective

Fabry's disease historical perspective in the news

Blogs on Fabry's disease historical perspective

Directions to Hospitals Treating Fabry's disease

Risk calculators and risk factors for Fabry's disease historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ghazal Sanadgol, M.D.[2]

Overview

Fabry's disease is a rare inherited genetic condition that leads to the α-galactosidase A enzyme deficiency in individuals. Fabry disease (or Anderson - Fabry disease) was first described separately by two physicians at the end of the 19th century. The feature and pathophysiology of the disease have been revealed through the years by various scientists.

Historical Perspective

Discovery

  • Fabry disease (or Anderson - Fabry disease) was first described separately by two physicians, Johannes Fabry in Germany and William Anderson in England, at the end of the 19th century.
  • In 1909, the neurological symptoms of the disease were described by Steiner and Voerner.
  • In 1925, the cardiac and ophthalmic complications and the possible hereditary feature of the disease were reported by Weicksel.
  • In 1947, systemic vascular involvement was demonstrated by Pompen et al. during Fabry's patients' autopsy.[2]
  • In 1953, the disease was recognized as a storage disease by Horbostel and Scriba.[3]
  • In 1963, Sweeley and Klionsky identified the aggregation of certain types of glycolipids in various cells of patients with Fabry's disease.[4]
  • In 1965, the nature of Fabry's disease was identified as the X-linked genetic disease by Opitz et al. for the first time.[5]
  • In 1970, the specific α-galactosidase A enzyme deficiency was recognized as a cause of the disease.[6]
  • In 2001, specific enzyme replacement therapy for Fabry's disease, namely Fabrazyme, was commercially introduced in Europe and in 2003 in the USA.[7]

References

  1. Mehta A, Beck M, Sunder-Plassmann G (2006). "Fabry Disease: Perspectives from 5 Years of FOS". PMID 21290707.
  2. POMPEN AW, RUITER M, WYERS HJ (1947). "Angiokeratoma corporis diffusum (universale) Fabry, as a sign of an unknown internal disease; two autopsy reports". Acta Med Scand. 128 (3): 234–55. doi:10.1111/j.0954-6820.1947.tb06596.x. PMID 18897399.
  3. HORNBOSTEL H, SCRIBA K (1953). "[Excision of skin in diagnosis of Fabry's angiokeratoma with cardio-vasorenal syndrome as phosphatide storage disease]". Klin Wochenschr. 31 (3–4): 68–9. doi:10.1007/BF01478472. PMID 13062573.
  4. SWEELEY CC, KLIONSKY B (1963). "FABRY'S DISEASE: CLASSIFICATION AS A SPHINGOLIPIDOSIS AND PARTIAL CHARACTERIZATION OF A NOVEL GLYCOLIPID". J Biol Chem. 238: 3148–50. PMID 14081947.
  5. Opitz JM, Stiles FC, Wise D, Race RR, Sanger R, Von Gemmingen GR; et al. (1965). "The Genetics of Angiokeratoma Corporis Diffusum (Fabry's Disease) and Its Linkage Relations with the Xg Locus". Am J Hum Genet. 17 (4): 325–42. PMC 1932618. PMID 17948499.
  6. Kint JA (1970). "Fabry's disease: alpha-galactosidase deficiency". Science. 167 (3922): 1268–9. doi:10.1126/science.167.3922.1268. PMID 5411915.
  7. Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ; et al. (2006). "Fabry disease: guidelines for the evaluation and management of multi-organ system involvement". Genet Med. 8 (9): 539–48. doi:10.1097/01.gim.0000237866.70357.c6. PMID 16980809.